Back

Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects WithElevated Risk

29 August 2017 (17:00 - 17:15)
Organised by:
Congress Presentation Part of: Clinical Trial Update 2 Lipids (Epidemiology and Prevention) ESC Premium Access ESC Congress 2017

About the speaker

Photo
Professor Terje Rolf Pedersen

Ulleval University Hospital, Oslo (Norway)

5 More presentations in this session

Presentation thumbnail
Prospective Randomized Evaluation of Celecoxib Integrated Safety vs. Ibuprofen of Naproxen
Professor S. Nissen (Cleveland, US)
Slides Video
Presentation thumbnail
Effect of the PCSK9 Inhibitor, Evolocumab, on the Composition of Coronary Atherosclerosis: Insights from the GLAGOV trial
Professor S. Nicholls (Melbourne, AU)
Slides Video
Presentation thumbnail
Empagliflozin reduces mortality in patients with type 2 diabetes after coronary artery bypass graft surgery: A sub-analysis of the EMPA-REG OUTCOME trial
Professor S. Verma (Toronto, CA)
Slides Video
Presentation thumbnail
Blood Pressure Levels for Initiation of Antihypertensive Drug Therapy and Targets of Blood Pressure Lowering in Intermediate Risk People without Cardiovascular Disease: Insights from the HOPE-3 Trial
Professor E. Lonn (Hamilton, CA)
Slides Video
Presentation thumbnail
One year clinical outcome of Early Administration of intravenous Beta blockers in patients with ST-elevation myocardial infarction before primary percutaneous coronary intervention.
Doctor V. Roolvink (Zwolle, NL)
Slides Video

Access the full session

Session thumbnail
Clinical Trial Update 2

The Event

Event poster

ESC Congress 2017

29 August 2017 17:00 CET
You may be interested in
thumbnail
Congress Presentation
Longer-term impact of PCSK9 inhibitors on major adverse cardiovascular events and all-cause mortality: a systematic review and meta-analysis of randomised controlled trials
28 August 2023
thumbnail
Webinar
LDL-C reduction postACS: strike early and strike strong
15 November 2021
thumbnail
Congress Presentation
Evolocumab rapidly reverses impaired coronary endothelial function in six weeks in people living with HIV and in patients with dyslipidemia
2 September 2019
thumbnail
Congress Presentation
PCSK9 inhibitors and incidence of arrhythmias in clinical practice: a phase IV multicentric study
18 April 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources